uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
uniQure N.V. (QURE) had 19 insider filings in the last 90 days, with the most recent on 2026-07-07. The full record for QURE runs to 41 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying QURE stock?
No insider purchases of QURE were filed in the last 90 days.
How many insiders are selling QURE stock?
36 insider sales of QURE were filed in the last 90 days, totaling $16.82M.
Where can I see QURE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks QURE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow QURE insider buys?
Create a free InsiderAlpha account and press Watch on this page to add QURE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
